Trial · NCT02582515
Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo
NCT02582515, Not applicable, Completed, University of California, Los Angeles; results first posted 2019-04-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo. Trials, record NCT02582515. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02582515
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo
- NCT number
- NCT02582515
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of California, Los Angeles
- Conditions
- Tourette Disorder, Chronic Tic Disorder
- Interventions
- D-cycloserine, Placebo
- First posted
- 2015-10-21
- Last updated
- 2019-04-25
- Results first posted
- 2019-04-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hopkins Motor/Vocal Tic Scale (HM/VTS) | Pre-treatment, One Week post-treatment | Participants can nominate up to five motor and five vocal tics they deem bothersome on the HM/VTS. Each bothersome tic is then rated by a clinician on a 5-point scale ranging from none (0) to severe (4). The individual tic scores are summed (minimum of 0 and maximum of 40) and averaged together to create an average tic severity score. Lower scores represent less tic severity, and higher scores indicate greater tic severity. The primary outcome will be the difference in the average score of the two bothersome tics on the HM/VTS that were targeted in treatment (range: 0-8). Change scores were calculated by subtracting the average of the two bothersome tics on the HM/VTS at post-treatment from the average of the two bothersome tics on the HM/VTS at the pre-treatment assessment. Positive scores indicate improvement/decrease in targeted tic severity, with negative scores indicating increase in targeted tic severity |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hopkins Motor/Vocal Tic Scale (HM/VTS) | Pre-treatment, One Week post-treatment | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Hopkins Motor/Vocal Tic Scale (HM/VTS) | D-cycloserine + Habit Reversal Training | 1.22 | Standard Deviation 0.62 | score on a scale | |
| Hopkins Motor/Vocal Tic Scale (HM/VTS) | Placebo + Habit Reversal Training | 0.70 | Standard Deviation 0.54 | score on a scale |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | D-cycloserine + Habit Reversal Training | 9 | |
| Overall Study | STARTED | Placebo + Habit Reversal Training | 11 | |
| Overall Study | Received Study Intervention | D-cycloserine + Habit Reversal Training | 9 | |
| Overall Study | Received Study Intervention | Placebo + Habit Reversal Training | 10 | |
| Overall Study | COMPLETED | D-cycloserine + Habit Reversal Training | 9 | |
| Overall Study | COMPLETED | Placebo + Habit Reversal Training | 10 | |
| Overall Study | NOT COMPLETED | D-cycloserine + Habit Reversal Training | 0 | |
| Overall Study | NOT COMPLETED | Placebo + Habit Reversal Training | 1 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Drowsiness | General disorders | D-cycloserine + Habit Reversal Training | 1 | 9 | 1 |
| other | Drowsiness | General disorders | Placebo + Habit Reversal Training | 0 | 10 | 0 |
| other | Difficulty Falling Asleep | General disorders | D-cycloserine + Habit Reversal Training | 1 | 9 | 1 |
| other | Difficulty Falling Asleep | General disorders | Placebo + Habit Reversal Training | 0 | 10 | 0 |
| other | Sore Throat | General disorders | D-cycloserine + Habit Reversal Training | 1 | 9 | 1 |
| other | Sore Throat | General disorders | Placebo + Habit Reversal Training | 0 | 10 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | D-cycloserine + Habit Reversal Training | 0 | 9 |
| Total, all-cause mortality | Placebo + Habit Reversal Training | 0 | 10 |
| Total, other adverse events | D-cycloserine + Habit Reversal Training | 3 | 9 |
| Total, other adverse events | Placebo + Habit Reversal Training | 0 | 10 |
| Total, serious adverse events | D-cycloserine + Habit Reversal Training | 0 | 9 |
| Total, serious adverse events | Placebo + Habit Reversal Training | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| D-cycloserine + Habit Reversal Training vs Placebo + Habit Reversal Training: deaths from any cause | Trial comparisons |
| D-cycloserine + Habit Reversal Training vs Placebo + Habit Reversal Training: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02582515
GET https://conductscience.org/api/trials/v1/NCT02582515/registered